Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program

Peter J. Houghton, Richard Lock, Hernan Carol, Christopher L. Morton, Doris Phelps, Richard Gorlick, E. Anders Kolb, Stephen T. Keir, C. Patrick Reynolds, Min H. Kang, John M. Maris, Amy W. Wozniak, Yongchuan Gu, William R. Wilson, Malcolm A. Smith

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: PR-104 is rapidly hydrolyzed to PR-104A in vivo, which is activated by reduction to the corresponding 5-hydroxylamine (PR-104H) and amine (PR-104M) to produce DNA interstrand cross-links. PR-104 activation can occur via hypoxia-dependent reductases and also independently of hypoxia by aldo-keto reductase (AKR) 1C3. Procedures: PR-104A was tested against the PPTP in vitro panel (10nM to 100μM), and PR-104 in vivo using a weekly×6 schedule at its maximum tolerated dose (MTD) of 550mg/kg. Subsequently PR-104 was tested at 270 and 110mg/kg. Pharmacokinetics for PR-104 and its metabolites were determined, as were levels of AKR1C3 RNA and protein in xenografts. Results: In vitro, the leukemia models were most sensitive to PR-104A. In vivo, PR-104 induced objective responses at its MTD in 21/34 solid tumor models and maintained complete responses against 7/7 acute lymphoblastic leukemia (ALL) models. At 270mg/kg and lower dose levels, PR-104 did not induce solid tumor regressions, suggesting a steep dose-response relationship. Pharmacokinetic analysis suggests higher systemic exposures to PR-104A and its metabolites in mice compared to those achievable in patients. Levels of AKR1C3 protein did not correlate with tumor responsiveness. Conclusions: As monotherapy, PR-104 demonstrated a high level of activity against both solid tumor and ALL models at its MTD, but the activity was almost completely lost at half the MTD dose for solid tumors. Pharmacokinetic data at the PR-104 MTD from human trials suggest that PR-104 metabolites may not reach the plasma exposures in children that were associated with high-level preclinical activity.

Original languageEnglish (US)
Pages (from-to)443-453
Number of pages11
JournalPediatric Blood and Cancer
Volume57
Issue number3
DOIs
StatePublished - Sep 2011

Fingerprint

Prodrugs
Pediatrics
Maximum Tolerated Dose
Pharmacokinetics
Neoplasms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
PR-104
Hypoxia
Hydroxylamine
Heterografts
Amines
Appointments and Schedules
Oxidoreductases
Leukemia
Proteins
RNA
PR-104A
DNA

Keywords

  • Developmental therapeutics
  • PR-104
  • Preclinical testing

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Houghton, P. J., Lock, R., Carol, H., Morton, C. L., Phelps, D., Gorlick, R., ... Smith, M. A. (2011). Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 57(3), 443-453. https://doi.org/10.1002/pbc.22921

Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program. / Houghton, Peter J.; Lock, Richard; Carol, Hernan; Morton, Christopher L.; Phelps, Doris; Gorlick, Richard; Kolb, E. Anders; Keir, Stephen T.; Reynolds, C. Patrick; Kang, Min H.; Maris, John M.; Wozniak, Amy W.; Gu, Yongchuan; Wilson, William R.; Smith, Malcolm A.

In: Pediatric Blood and Cancer, Vol. 57, No. 3, 09.2011, p. 443-453.

Research output: Contribution to journalArticle

Houghton, PJ, Lock, R, Carol, H, Morton, CL, Phelps, D, Gorlick, R, Kolb, EA, Keir, ST, Reynolds, CP, Kang, MH, Maris, JM, Wozniak, AW, Gu, Y, Wilson, WR & Smith, MA 2011, 'Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 57, no. 3, pp. 443-453. https://doi.org/10.1002/pbc.22921
Houghton, Peter J. ; Lock, Richard ; Carol, Hernan ; Morton, Christopher L. ; Phelps, Doris ; Gorlick, Richard ; Kolb, E. Anders ; Keir, Stephen T. ; Reynolds, C. Patrick ; Kang, Min H. ; Maris, John M. ; Wozniak, Amy W. ; Gu, Yongchuan ; Wilson, William R. ; Smith, Malcolm A. / Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program. In: Pediatric Blood and Cancer. 2011 ; Vol. 57, No. 3. pp. 443-453.
@article{9c196d66f6664b76a2fbbe31086ef92f,
title = "Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program",
abstract = "Background: PR-104 is rapidly hydrolyzed to PR-104A in vivo, which is activated by reduction to the corresponding 5-hydroxylamine (PR-104H) and amine (PR-104M) to produce DNA interstrand cross-links. PR-104 activation can occur via hypoxia-dependent reductases and also independently of hypoxia by aldo-keto reductase (AKR) 1C3. Procedures: PR-104A was tested against the PPTP in vitro panel (10nM to 100μM), and PR-104 in vivo using a weekly×6 schedule at its maximum tolerated dose (MTD) of 550mg/kg. Subsequently PR-104 was tested at 270 and 110mg/kg. Pharmacokinetics for PR-104 and its metabolites were determined, as were levels of AKR1C3 RNA and protein in xenografts. Results: In vitro, the leukemia models were most sensitive to PR-104A. In vivo, PR-104 induced objective responses at its MTD in 21/34 solid tumor models and maintained complete responses against 7/7 acute lymphoblastic leukemia (ALL) models. At 270mg/kg and lower dose levels, PR-104 did not induce solid tumor regressions, suggesting a steep dose-response relationship. Pharmacokinetic analysis suggests higher systemic exposures to PR-104A and its metabolites in mice compared to those achievable in patients. Levels of AKR1C3 protein did not correlate with tumor responsiveness. Conclusions: As monotherapy, PR-104 demonstrated a high level of activity against both solid tumor and ALL models at its MTD, but the activity was almost completely lost at half the MTD dose for solid tumors. Pharmacokinetic data at the PR-104 MTD from human trials suggest that PR-104 metabolites may not reach the plasma exposures in children that were associated with high-level preclinical activity.",
keywords = "Developmental therapeutics, PR-104, Preclinical testing",
author = "Houghton, {Peter J.} and Richard Lock and Hernan Carol and Morton, {Christopher L.} and Doris Phelps and Richard Gorlick and Kolb, {E. Anders} and Keir, {Stephen T.} and Reynolds, {C. Patrick} and Kang, {Min H.} and Maris, {John M.} and Wozniak, {Amy W.} and Yongchuan Gu and Wilson, {William R.} and Smith, {Malcolm A.}",
year = "2011",
month = "9",
doi = "10.1002/pbc.22921",
language = "English (US)",
volume = "57",
pages = "443--453",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program

AU - Houghton, Peter J.

AU - Lock, Richard

AU - Carol, Hernan

AU - Morton, Christopher L.

AU - Phelps, Doris

AU - Gorlick, Richard

AU - Kolb, E. Anders

AU - Keir, Stephen T.

AU - Reynolds, C. Patrick

AU - Kang, Min H.

AU - Maris, John M.

AU - Wozniak, Amy W.

AU - Gu, Yongchuan

AU - Wilson, William R.

AU - Smith, Malcolm A.

PY - 2011/9

Y1 - 2011/9

N2 - Background: PR-104 is rapidly hydrolyzed to PR-104A in vivo, which is activated by reduction to the corresponding 5-hydroxylamine (PR-104H) and amine (PR-104M) to produce DNA interstrand cross-links. PR-104 activation can occur via hypoxia-dependent reductases and also independently of hypoxia by aldo-keto reductase (AKR) 1C3. Procedures: PR-104A was tested against the PPTP in vitro panel (10nM to 100μM), and PR-104 in vivo using a weekly×6 schedule at its maximum tolerated dose (MTD) of 550mg/kg. Subsequently PR-104 was tested at 270 and 110mg/kg. Pharmacokinetics for PR-104 and its metabolites were determined, as were levels of AKR1C3 RNA and protein in xenografts. Results: In vitro, the leukemia models were most sensitive to PR-104A. In vivo, PR-104 induced objective responses at its MTD in 21/34 solid tumor models and maintained complete responses against 7/7 acute lymphoblastic leukemia (ALL) models. At 270mg/kg and lower dose levels, PR-104 did not induce solid tumor regressions, suggesting a steep dose-response relationship. Pharmacokinetic analysis suggests higher systemic exposures to PR-104A and its metabolites in mice compared to those achievable in patients. Levels of AKR1C3 protein did not correlate with tumor responsiveness. Conclusions: As monotherapy, PR-104 demonstrated a high level of activity against both solid tumor and ALL models at its MTD, but the activity was almost completely lost at half the MTD dose for solid tumors. Pharmacokinetic data at the PR-104 MTD from human trials suggest that PR-104 metabolites may not reach the plasma exposures in children that were associated with high-level preclinical activity.

AB - Background: PR-104 is rapidly hydrolyzed to PR-104A in vivo, which is activated by reduction to the corresponding 5-hydroxylamine (PR-104H) and amine (PR-104M) to produce DNA interstrand cross-links. PR-104 activation can occur via hypoxia-dependent reductases and also independently of hypoxia by aldo-keto reductase (AKR) 1C3. Procedures: PR-104A was tested against the PPTP in vitro panel (10nM to 100μM), and PR-104 in vivo using a weekly×6 schedule at its maximum tolerated dose (MTD) of 550mg/kg. Subsequently PR-104 was tested at 270 and 110mg/kg. Pharmacokinetics for PR-104 and its metabolites were determined, as were levels of AKR1C3 RNA and protein in xenografts. Results: In vitro, the leukemia models were most sensitive to PR-104A. In vivo, PR-104 induced objective responses at its MTD in 21/34 solid tumor models and maintained complete responses against 7/7 acute lymphoblastic leukemia (ALL) models. At 270mg/kg and lower dose levels, PR-104 did not induce solid tumor regressions, suggesting a steep dose-response relationship. Pharmacokinetic analysis suggests higher systemic exposures to PR-104A and its metabolites in mice compared to those achievable in patients. Levels of AKR1C3 protein did not correlate with tumor responsiveness. Conclusions: As monotherapy, PR-104 demonstrated a high level of activity against both solid tumor and ALL models at its MTD, but the activity was almost completely lost at half the MTD dose for solid tumors. Pharmacokinetic data at the PR-104 MTD from human trials suggest that PR-104 metabolites may not reach the plasma exposures in children that were associated with high-level preclinical activity.

KW - Developmental therapeutics

KW - PR-104

KW - Preclinical testing

UR - http://www.scopus.com/inward/record.url?scp=79960189045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960189045&partnerID=8YFLogxK

U2 - 10.1002/pbc.22921

DO - 10.1002/pbc.22921

M3 - Article

C2 - 21744473

AN - SCOPUS:79960189045

VL - 57

SP - 443

EP - 453

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 3

ER -